Literature DB >> 3494061

Induction of colony stimulating factor in vivo by recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha 1.

S N Vogel, S D Douches, E N Kaufman, R Neta.   

Abstract

In response to a potent inflammatory challenge, such as Gram-negative endotoxin, a number of cytokines are induced that, in turn, mediate many of the pathophysiologic alterations associated with endotoxicity. In this study, we have observed two endotoxin-associated monokines, recombinant interleukin-1 alpha (rIL 1 alpha) and recombinant tumor necrosis factor alpha (rTNF alpha), to induce colony stimulating factor (CSF) in vivo. The CSF activities produced in response to rIL 1 alpha or rTNF alpha gave rise to a mixture of granulocyte-macrophage colonies and were induced in a dose- and time-dependent fashion, peaking within 3 hr of cytokine injection (preceding peak CSF induction by endotoxin by several hours). Combined injection of suboptimal concentrations of rIL 1 alpha and rTNF alpha were additive, and simultaneous injection of optimal concentrations of each failed to increase CSF levels over that observed with either cytokine alone. Unlike endotoxin, neither cytokine induced interferon in vivo. These findings extend our understanding of the cytokine cascade that is operative in an inflammatory response and may account for many of the observed hematopoietic alterations that accompany inflammation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3494061

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Radiation protective effect of an extract from Chelidonium majus.

Authors:  Jie-Young Song; Hyun-Ok Yang; Ji-Young Shim; Young-Soo Han; In-Sung Jung; Yeon-Sook Yun
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

2.  Occurrence of interleukin-1 in human synovial fluid: detection by RIA, bioassay and presence of bioassay-inhibiting factors.

Authors:  J B Smith; M H Bocchieri; L Sherbin-Allen; M Borofsky; J L Abruzzo
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

Review 3.  Use of immune modulators in nonspecific therapy of bacterial infections.

Authors:  M T Vogels; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance.

Authors:  B E Henricson; W R Benjamin; S N Vogel
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

5.  An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance.

Authors:  B E Henricson; R Neta; S N Vogel
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  Roles of interleukin-1 and tumor necrosis factor in lipopolysaccharide-induced hypoglycemia.

Authors:  S N Vogel; B E Henricson; R Neta
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

7.  Primary role of interleukin-1 alpha and interleukin-1 beta in lipopolysaccharide-induced hypoglycemia in mice.

Authors:  Senri Oguri; Katsutoshi Motegi; Yoichiro Iwakura; Yasuo Endo
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 8.  Role of interleukin-1 in hematopoiesis.

Authors:  M A Moore
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

9.  Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha.

Authors:  A Minami; K Fujimoto; Y Ozaki; S Nakamura
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

10.  Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes.

Authors:  S N Vogel; E N Kaufman; M D Tate; R Neta
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.